Diagnostic markers for glaucoma: a patent and literature review (2013-2019)

References

• Holden BA, Fricke TR, Wilson DA, et al. Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050. Ophthalmology. 2016;123:1036–1042.
   PubMed Web of Science ®Google Scholar
• Tan NYQ, Sng CCA, Jonas JB, et al. Glaucoma in myopia: diagnostic dilemmas. Br J Ophthalmol. published online 2019 April 30. DOI:10.1136/bjophthalmol-2018-313530.
   Google Scholar
• Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90:262–267.
   PubMed Web of Science ®Google Scholar
• Keller KE, Bradley JM, Vranka JA, et al. Segmental versican expression in the trabecular meshwork and involvement in outflow facility. Invest Ophthalmol Vis Sci. 2011;52:5049–5057.
   PubMed Web of Science ®Google Scholar
• Colligris B, Crooke A, Gasull X, et al. Recent patents and developments in glaucoma biomarkers. Recent Pat Endocr Metab Immune Drug Discov. 2012;6:224–234.
   PubMedGoogle Scholar
• Nocentini A, Ferraroni M, Carta F, et al. Benzenesulfonamides incorporating flexible triazole moieties are highly effective carbonic anhydrase inhibitors: synthesis and kinetic, crystallographic, computational, and intraocular pressure lowering investigations. J Med Chem. 2016;59:10692–10704.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Structure-based drug discovery of carbonic anhydrase inhibitors. J Enzyme Inhib Med Chem. 2012;27:759–772.
   PubMed Web of Science ®Google Scholar
• Carradori S, Mollica A, De Monte C, et al. Nitric oxide donors and selective carbonic anhydrase inhibitors: a dual pharmacological approach for the treatment of glaucoma, cancer and osteoporosis. Molecules. 2015;20:5667–5679.
   PubMed Web of Science ®Google Scholar
• Scozzafava A, Supuran CT. Glaucoma and the applications of carbonic anhydrase inhibitors. Subcell Biochem. 2014;75:349–359.
   PubMedGoogle Scholar
• Masini E, Carta F, Scozzafava A, et al. Antiglaucoma carbonic anhydrase inhibitors: a patent review. Expert Opin Ther Pat. 2013;23:705–716.
   PubMed Web of Science ®Google Scholar
• Lolak N, Akocak S, Bua S, et al. Design and synthesis of novel 1,3-diaryltriazene-substituted sulfonamides as potent and selective carbonic anhydrase II inhibitors. Bioorg Chem. 2018;77:542–547.
   PubMed Web of Science ®Google Scholar
• Kumar R, Vats L, Bua S, et al. Design and synthesis of novel benzenesulfonamide containing 1,2,3-triazoles as potent human carbonic anhydrase isoforms I, II, IV and IX inhibitors. Eur J Med Chem. 2018;155:545–551.
   PubMed Web of Science ®Google Scholar
• Nocentini A, Ceruso M, Bua S, et al. Discovery of β-adrenergic receptors blocker-carbonic anhydrase inhibitor hybrids for multitargeted antiglaucoma therapy. J Med Chem. 2018;61:5380–5394.
   PubMed Web of Science ®Google Scholar
• Quigley HA. Glaucoma. Lancet. 2011;377:1367–1377.
   PubMed Web of Science ®Google Scholar
• Zhang K, Zhang L, Weinreb RN. Ophthalmic drug discovery: novel targets and mechanisms for retinal disease and glaucoma. Nat Rev Drug Discovery. 2012;11:541–559.
   PubMed Web of Science ®Google Scholar
• Ehlers N, Hansen FK, Aasved H. Biometric correlations of corneal thickness. Acta Ophthalmol (Copenh). 1975;53:652–659.
   PubMed Web of Science ®Google Scholar
• Tham YC, Li X, Wong TY, et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014;121:2081–2090.
   PubMed Web of Science ®Google Scholar
• Carta F, Supuran CT, Scozzafava A. Novel therapies for glaucoma: a patent review 2007−2011. Expert Opin Ther Pat. 2012;22:79–88.
   PubMed Web of Science ®Google Scholar
• Glaucoma. Humanitas mater domini. [cited 2019 Jun 4]. Available from: https://www.materdomini.it/malattie/glaucoma/
   Google Scholar
• Glaucoma. IRCCS Fondazione G.B. Bietti per lo Studio e la Ricerca in Oftalmologia – ONLUS. [cited 2019 May 26]. Available from: https://www.fondazionebietti.it/it/glaucoma
   Google Scholar
• Stamper RL. A history of intraocular pressure and its measurement. Optom Vis Sci. 2011;88:E16–28.
   PubMed Web of Science ®Google Scholar
• Goldmann H. Un nouveau tonometre d’applanation. Bull Soc Ophtalmol Fr. 1955;67:474–478.
   Google Scholar
• Whitacre MM, Stein RA, Hassanein K. The effect of corneal thickness on applanation tonometry. Am J Ophthalmol. 1993;115:592–596.
   PubMed Web of Science ®Google Scholar
• Herndon LW, Choudhri SA, Cox T, et al. Central corneal thickness in normal, glaucomatous, and ocular hypertensive eyes. Arch Ophthalmol. 1997;115:1137–1141.
   PubMed Web of Science ®Google Scholar
• Wolfs RC, Klaver CC, Vingerling JR, et al. Distribution of central corneal thickness and its association with intraocular pressure: the Rotterdam study. Am J Ophthalmol. 1997;123:767–772.
   PubMed Web of Science ®Google Scholar
• Brandt JD, Beiser JA, Kass MA, et al. Central corneal thickness in the ocular hypertension treatment study (OHTS). Ophthalmology. 2001;108:1779–1788.
   PubMed Web of Science ®Google Scholar
• Tonnu PA, Ho T, Newson T, et al. The influence of central corneal thickness and age on intraocular pressure measured by pneumotonometry, non-contact tonometry, the Tono-Pen XL, and Goldmann applanation tonometry. Br J Ophthalmol. 2005;89:851–854.
   PubMed Web of Science ®Google Scholar
• Feng R, Luk SMH, Wu CHK, et al. Perceptions of training in gonioscopy. Eye (Lond). 2019 July 2 published online. DOI:10.1038/s41433-019-0498-8.
   Google Scholar
• Sakata LM, Lavanya R, Friedman DS, et al. Comparison of gonioscopy and anterior segment ocular coherence tomography in detecting angle closure in different quadrants of the anterior chamber angle. Ophthalmology. 2008;115:769–774.
   PubMed Web of Science ®Google Scholar
• Ting DSJ, Ghosh S. Central toxic keratopathy after contact lens wear and mechanical debridement: clinical characteristics, and visual and corneal tomographic outcomes. Eye Contact Lens. 2019;45:e15–e23.
   PubMed Web of Science ®Google Scholar
• Hau WKT, Yan BPY. Role of intravascular imaging in primary PCI. Source primary angioplasty: a practical guide [Internet]. Singapore: Springer; 2018.
   Google Scholar
• Otis LL, Everett MJ, Sathyam US, et al. Optical coherence tomography: a new imaging technology for dentistry. J Am Dent Assoc. 2000;131:511–514.
   PubMed Web of Science ®Google Scholar
• Igarashi R, Ochiai S, Sakaue Y, et al. Optical coherence tomography angiography of the peripapillary capillaries in primary open-angle and normal-tension glaucoma. PLoS One. 2017;12:e0184301.
   PubMed Web of Science ®Google Scholar
• Fogagnolo P, Digiuni M, Montesano G, et al. Compass fundus automated perimetry. Eur J Ophthalmol. 2018;28:481–490.
   PubMed Web of Science ®Google Scholar
• Shigeru K, Kei T, Masakazu N, et al. Method for determination of onset risk of glaucoma. US2010196895. 2010.
   Google Scholar
• Shigeru K, Kei T, Masakazu N, et al. Method for determination of onset risk of glaucoma. US8431345. 2013.
   Google Scholar
• Shigeru K, Kei T, Masakazu N, et al. Method for determination of onset risk of glaucoma. US2013012408. 2013.
   Google Scholar
• Shigeru K, Kei T, Masakazu N, et al. Method for determination of onset risk of glaucoma. US2013210668. 2013.
   Google Scholar
• Gaasterland T, Gaasterland DE Methods of identifying biomarkers associated with or causative of the progression of disease. US2015315645. 2015.
   Google Scholar
• Gaasterland T, Gaasterland DE Methods of identifying biomarkers associated with or causative of the progression of disease, in particular for use in prognosticating primary open angle glaucoma. WO2015171457. 2015.
   Google Scholar
• Liu Y, Allingham RR. Major review: molecular genetics of primary open-angle glaucoma. Exp Eye Res. 2017;160:62–84.
   PubMed Web of Science ®Google Scholar
• Sheffield VC, Stone EM, Alward WL, et al. Genetic linkage of familial open angle glaucoma to chromosome 1q21-q31. Nat Genet. 1993;4:47–50.
   PubMed Web of Science ®Google Scholar
• Akiyama M, Yatsu K, Ota M, et al. Microsatellite analysis of the GLC1B locus on chromosome 2 points to NCK2 as a new candidate gene for normal tension glaucoma. Br J Ophthalmol. 2008;92:1293–1296.
   PubMed Web of Science ®Google Scholar
• Keller KE, Yang YF, Sun YY, et al. Interleukin-20 receptor expression in the trabecular meshwork and its implication in glaucoma. J Ocul Pharmacol Ther. 2014;30:267–276.
   PubMed Web of Science ®Google Scholar
• Trifan OC, Traboulsi EI, Stoilova D, et al. A third locus (GLC1D) for adult-onset primary open-angle glaucoma maps to the 8q23 region. Am J Ophthalmol. 1998;126:17–28.
   PubMed Web of Science ®Google Scholar
• Rezaie T, Child A, Hitchings R, et al. Adult-onset primary open-angle glaucoma caused by mutations in optineurin. Science. 2002;295:1077–1079.
   PubMed Web of Science ®Google Scholar
• Pasutto F, Keller KE, Weisschuh N, et al. Variants in ASB10 are associated with open-angle glaucoma. Hum Mol Genet. 2012;21:1336–1349.
   PubMed Web of Science ®Google Scholar
• Monemi S, Spaeth G, DaSilva A, et al. Identification of a novel adultonset primary open-angle glaucoma (POAG) gene on 5q22.1. Hum Mol Genet. 2005;14:725–733.
   PubMed Web of Science ®Google Scholar
• Lin Y, Liu T, Li J, et al. A genome-wide scan maps a novel autosomal dominant juvenile-onset open-angle glaucoma locus to 2p15-16. Mol Vis. 2008;14:739–744.
   PubMed Web of Science ®Google Scholar
• Allingham RR, Wiggs JL, Hauser ER, et al. Early adult-onset POAG linked to 15q11-13 using ordered subset analysis. Invest Ophthalmol Vis Sci. 2005;46:2002–2005.
   PubMed Web of Science ®Google Scholar
• Wiggs JL, Lynch S, Ynagi G, et al. A genomewide scan identifies novel early-onset primary open-angle glaucoma loci on 9q22 and 20p12. Am J Hum Genet. 2004;74:1314–1320.
   PubMed Web of Science ®Google Scholar
• Baird PN, Foote SJ, Mackey DA, et al. Evidence for a novel glaucoma locus at chromosome 3p21-22. Hum Genet. 2005;117:249–257.
   PubMed Web of Science ®Google Scholar
• Fan BJ, Ko WC, Wang DY, et al. Fine mapping of new glaucoma locus GLC1M and exclusion of neuregulin 2 as the causative gene. Mol Vis. 2007;13:779–784.
   PubMed Web of Science ®Google Scholar
• Wang DY, Fan BJ, Chua JK, et al. A genome-wide scan maps a novel juvenile-onset primary open-angle glaucoma locus to 15q. Invest Ophthalmol Vis Sci. 2006;47:5315–5321.
   PubMed Web of Science ®Google Scholar
• Liu Y, Liu W, Crooks K, et al. No evidence of association of heterozygous NTF4 mutations in patients with primary open-angle glaucoma. Am J Hum Genet. 2010;86:498–499.
   PubMed Web of Science ®Google Scholar
• Bennett SR, Alward WL, Folberg R. An autosomal dominant form of low-tension glaucoma. Am J Ophthalmol. 1989;108:238–244.
   PubMed Web of Science ®Google Scholar
• Stone EM, Fingert JH, Alward WL, et al. Identification of a gene that causes primary open angle glaucoma. Science. 1997;275:668–670.
   PubMed Web of Science ®Google Scholar
• Mahmood SU, Saeed A, Bua S, et al. Synthesis, biological evaluation and computational studies of novel iminothiazolidinone benzenesulfonamides as potent carbonic anhydrase II and IX inhibitors. Bioorg Chem. 2018;77:381–386.
   PubMed Web of Science ®Google Scholar
• Richards JE, Lichter PR, Boehnke M, et al. Mapping of a gene for autosomal dominant juvenile-onset open-angle glaucoma to chromosome Iq. Am J Hum Genet. 1994;54:62–70.
   PubMed Web of Science ®Google Scholar
• Wiggs JL, Haines JL, Paglinauan C, et al. Genetic linkage of autosomal dominant juvenile glaucoma to 1q21-q31 in three affected pedigrees. Genomics. 1994;212:299–303.
   Google Scholar
• Morissette J, Côté G, Anctil JL, et al. A common gene for juvenile and adult-onset primary open-angle glaucomas confined on chromosome 1q. Am J Hum Genet. 1995;56:1431–1442.
   PubMed Web of Science ®Google Scholar
• Yue BY. Myocilin and Optineurin: differential characteristics and functional consequences. Taiwan J Ophthalmol. 2011;1:6–11.
   PubMedGoogle Scholar
• Lopez-Martinez F, Lopez-Garrido MP, Sanchez-Sanchez F, et al. Role of MYOC and OPTN sequence variations in Spanish patients with primary open-angle glaucoma. Mol Vis. 2007;13:862–872.
   PubMed Web of Science ®Google Scholar
• Melki R, Belmouden A, Brezin A, et al. Myocilin analysis by DHPLC in French POAG patients: increased prevalence of Q368X mutation. Hum Mutat. 2003;22:179.
   PubMedGoogle Scholar
• Craig JE, Baird PN, Healey DL, et al. Evidence for genetic heterogeneity within eight glaucoma families, with the GLC1A Gln368STOP mutation being an important phenotypic modifier. Ophthalmology. 2001;108:1607–1620.
   PubMed Web of Science ®Google Scholar
• Useinovna DL, Leonidovich LS, Rifovna ZA et al. Method for detecting p.q368x myocilin (myoc) gene mutation causing primary open-angle glaucoma. RU2014107633 (2015)
   Google Scholar
• Xie L, Mao M, Wang C, et al. Potential biomarkers for primary open-angle glaucoma identified by long noncoding RNA profiling in the aqueous humor. Am J Pathol. 2019;189:739–752.
   PubMed Web of Science ®Google Scholar
• Warner JR. The economics of ribosome biosynthesis in yeast. Trends Biochem Sci. 1999;24:437–440.
   PubMed Web of Science ®Google Scholar
• Ebert MS, Sharp PA. MicroRNA sponges: progress and possibilities. RNA. 2010;16:2043–2050.
   PubMed Web of Science ®Google Scholar
• Wu H, Yang L, Chen LL. The diversity of long noncoding RNAs and their generation. Trends Genet. 2017;33:540–552.
   PubMed Web of Science ®Google Scholar
• Jandura A, Krause HM. The new RNA world: growing evidence for long noncoding RNA functionality. Trends Genet. 2017;33:665–676.
   PubMed Web of Science ®Google Scholar
• Sauvageau M, Goff LA, Lodato S, et al. Multiple knockout mouse models reveal lincRNAs are required for life and brain development. Elife. 2013;2:e01749.
   PubMed Web of Science ®Google Scholar
• Cech TR, Steitz JA. The noncoding RNA revolution-trashing old rules to forge new ones. Cell. 2014;157:77–94.
   PubMed Web of Science ®Google Scholar
• Jiang B, Xie L, Zhang L, et al. Molecular marker lncRNAs ENST00000508241 for diagnosing glaucoma, reagent kit and application. CN106978507. 2017.
   Google Scholar
• Jiang B, Xie L, Zhang L, et al. Molecular marker lncRNAs TCONS_00025577 for diagnosing glaucoma, reagent kit and application. CN106978508. 2017.
   Google Scholar
• Jiang B, Xie L, Zhang L, et al. Molecular marker lncRNAs ENST00000607393 for diagnosing glaucoma, reagent kit and application. CN106978509. 2017.
   Google Scholar
• Jiang B, Xie L, Zhang L, et al. Glaucoma diagnosis molecular marker lncRNAs NR_026887, kit and application. CN106987651. 2017.
   Google Scholar
• Jiang B, Xie L, Zhang L, et al. Molecular marker IncRNAs ENST00000564363 for diagnosing glaucoma, kit and application. CN107034303. 2017.
   Google Scholar
• Jiang B, Xie L, Zhang L, et al. Glaucoma diagnosis molecular marker lncRNAs T342877, kit and application. CN107043824. 2017.
   Google Scholar
• Jiang B, Xie L, Zhang L, et al. Glaucoma diagnose molecular marker lncRNAsT267384, kit and application. CN107142316. 2017.
   Google Scholar
• Ban N, Siegfried CJ, Apte RS. Monitoring neurodegeneration in glaucoma: therapeutic implications. Trends Mol Med. 2018;24:7–17.
   PubMed Web of Science ®Google Scholar
• Biomarkers Definitions Working Group. Biomarkers and surrogate end points: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69:89–95.
   PubMed Web of Science ®Google Scholar
• Galasko D. Biological markers and the treatment of Alzheimer’s disease. J Mol Neurosci. 2001;17:119–125.
   PubMed Web of Science ®Google Scholar
• Prentice RL. Surrogate end points in clinical trials: definition and operational criteria. Stat Med. 1989;8:431–440.
   PubMed Web of Science ®Google Scholar
• Apte RS, Yoshino J GDF15 in glaucoma and methods of use thereof. WO2017132673. 2017.
   Google Scholar
• Ban N, Siegfried CJ, Lin JB, et al. GDF15 is elevated in mice following retinal ganglion cell death and in glaucoma patients. JCI Insight. 2017;2:91455.
   PubMed Web of Science ®Google Scholar
• Andrews R, Ressiniotis T, Turnbull DM, et al. The role of mitochondrial haplogroups in primary open angle glaucoma. Br J Ophthalmol. 2006;90:488–490.
   PubMed Web of Science ®Google Scholar
• Collins DW, Gudiseva HV, Trachtman B, et al. Association of primary open-angle glaucoma with mitochondrial variants and haplogroups common in African Americans. Mol Vis. 2016;22:454–471.
   PubMed Web of Science ®Google Scholar
• Abu-Amero KK, González AM, Osman EA, et al. Susceptibility to primary angle closure glaucoma in Saudi Arabia: the possible role of mitochondrial DNA ancestry informative haplogroups. Mol Vis. 2011;17:2171–2176.
   PubMed Web of Science ®Google Scholar
• Collins DW, Gudiseva VH, O’brien J, et al. Methods for screening and diagnosing glaucoma. WO2017189951. 2017.
   Google Scholar
• Fridrich S, Karmilin K, Stöcker W. Handling Metalloproteinases. Curr Protoc Protein Sci. 2016;83:21.16.1–21.16.20.
   PubMedGoogle Scholar
• Arolas JL, Broder C, Jefferson T, et al. Structural basis for the shed dase function of human meprin metalloproteinase at the plasma membrane. Proc Natl Acad Sci U S A. 2012;109:16131–16136.
   PubMed Web of Science ®Google Scholar
• Baker AH, Edwards DR, Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci. 2002;115:3719–3727.
   PubMed Web of Science ®Google Scholar
• Santamaria S, Nuti E, Cercignani G, et al. Kinetic characterization of 4,4ʹ-biphenylsulfonamides as selective non-zinc binding MMP inhibitors. J Enzyme Inhib Med Chem. 2015;30:947–954.
   PubMed Web of Science ®Google Scholar
• Bode W, Gomis-Ruth FX, Stockler W. Astacins, serralysins, snake venom and matrix metalloproteinases exhibit identical zinc-binding environments (HEXXHXXGXXH and Met-turn) and topologies and should be grouped into a common family, the “metzincins.”. FEBS Lett. 1993;331:134–140.
   PubMed Web of Science ®Google Scholar
• Colige A, Li SW, Sieron AL, et al. cDNA cloning and expression of bovine procollagen I N-proteinase: a new member of the superfamily of zinc-metalloproteinases with binding sites for cells and other matrix components. Proc Natl Acad Sci USA. 1997;94:2374–2379.
   PubMed Web of Science ®Google Scholar
• Ra HJ, Parks WC. Control of matrix metalloproteinase catalytic activity. Matrix Biol. 2007;26:587–596.
   PubMed Web of Science ®Google Scholar
• Scozzafava A, Supuran CT. Protease inhibitors: synthesis of matrix metalloproteinase and bacterial collagenase inhibitors incorporating 5-amino-2-mercapto-1,3,4-thiadiazole zinc binding functions. Bioorg Med Chem Lett. 2002;12:2667–2672.
   PubMed Web of Science ®Google Scholar
• Guo MS, Wu YY, Liang ZB. Hyaluronic acid increases MMP-2 and MMP-9 expressions in cultured trabecular meshwork cells from patients with primary open-angle glaucoma. Mol Vis. 2012;18:1175–1181.
   PubMed Web of Science ®Google Scholar
• Knepper PA, Goossens W, Hvizd M, et al. Glycosaminoglycans of the human trabecular meshwork in primary open-angle glaucoma. Invest Ophthalmol Vis Sci. 1996;37:1360–1367.
   PubMed Web of Science ®Google Scholar
• Khokhlova AS, Markelova EV, Dogadova LP, et al. Method for predicting rate of progression of glaucoma optic neuropathy. RU2665005. 2018.
   Google Scholar
• Messmer EM, von Lindenfels V, Garbe A, et al. Matrix metalloproteinase 9 testing in dry eye disease using a commercially available point-of-care immunoassay. Ophthalmology. 2016;123:2300–2308.
   PubMed Web of Science ®Google Scholar
• Funke S, Beck S, Lorenz K, et al. Analysis of the effects of preservative-free tafluprost on the tear proteome. Am J Transl Res. 2016;8:4025–4039.
   PubMed Web of Science ®Google Scholar